Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Repare Therapeutics (RPTX)

Repare Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RPTX
DateTimeSourceHeadlineSymbolCompany
10/01/202512:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPTXRepare Therapeutics Inc
09/01/202521:05Business WireRepare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost ReductionsNASDAQ:RPTXRepare Therapeutics Inc
12/12/202421:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPTXRepare Therapeutics Inc
12/12/202421:20Business WireRepare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical TrialNASDAQ:RPTXRepare Therapeutics Inc
10/12/202421:05Business WireRepare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical TrialNASDAQ:RPTXRepare Therapeutics Inc
14/11/202422:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RPTXRepare Therapeutics Inc
14/11/202414:42Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RPTXRepare Therapeutics Inc
12/11/202412:05Business WireRepare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of CamonsertibNASDAQ:RPTXRepare Therapeutics Inc
07/11/202413:33Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RPTXRepare Therapeutics Inc
07/11/202412:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RPTXRepare Therapeutics Inc
07/11/202412:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPTXRepare Therapeutics Inc
07/11/202412:05Business WireRepare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:RPTXRepare Therapeutics Inc
23/10/202410:05Business WireRepare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical TrialNASDAQ:RPTXRepare Therapeutics Inc
14/10/202411:05Business WireRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase InhibitorNASDAQ:RPTXRepare Therapeutics Inc
30/09/202420:05Business WireRepare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual MeetingNASDAQ:RPTXRepare Therapeutics Inc
23/09/202411:05Business WireRepare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic CancersNASDAQ:RPTXRepare Therapeutics Inc
13/09/202411:00Business WireRepare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024NASDAQ:RPTXRepare Therapeutics Inc
28/08/202420:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPTXRepare Therapeutics Inc
28/08/202420:05Business WireRepare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical PortfolioNASDAQ:RPTXRepare Therapeutics Inc
27/08/202411:05Business WireRepare Therapeutics to Participate in Two Upcoming Investor ConferencesNASDAQ:RPTXRepare Therapeutics Inc
20/08/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RPTXRepare Therapeutics Inc
07/08/202413:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPTXRepare Therapeutics Inc
06/08/202420:41Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RPTXRepare Therapeutics Inc
06/08/202420:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RPTXRepare Therapeutics Inc
06/08/202420:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPTXRepare Therapeutics Inc
06/08/202420:05Business WireRepare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:RPTXRepare Therapeutics Inc
16/07/202413:00PR Newswire (Canada)Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fundNASDAQ:RPTXRepare Therapeutics Inc
26/06/202414:30Business WireRepare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRINASDAQ:RPTXRepare Therapeutics Inc
17/06/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPTXRepare Therapeutics Inc
10/06/202411:05Business WireRepare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical TrialNASDAQ:RPTXRepare Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RPTX